SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 287 filers reported holding SAGE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21 | -55.3% | 1 | 0.0% | 0.00% | – |
| Q2 2023 | $47 | +11.9% | 1 | 0.0% | 0.00% | – |
| Q1 2023 | $42 | +10.5% | 1 | 0.0% | 0.00% | – |
| Q4 2022 | $38 | – | 1 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 1 | -93.3% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 15 | -71.2% | 0.00% | – |
| Q4 2021 | $2,000 | 0.0% | 52 | 0.0% | 0.00% | – |
| Q3 2021 | $2,000 | +100.0% | 52 | +173.7% | 0.00% | – |
| Q2 2021 | $1,000 | – | 19 | +90.0% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 10 | -95.6% | 0.00% | -100.0% |
| Q4 2019 | $16,000 | -48.4% | 226 | 0.0% | 0.00% | -50.0% |
| Q3 2019 | $31,000 | -22.5% | 226 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $40,000 | +14.3% | 226 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $35,000 | +105.9% | 226 | +25.6% | 0.00% | +50.0% |
| Q4 2018 | $17,000 | -29.2% | 180 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $24,000 | -11.1% | 180 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $27,000 | +237.5% | 180 | +221.4% | 0.00% | +100.0% |
| Q1 2018 | $8,000 | – | 56 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |